Sill H, Aguiar R C, Schmidt H, Hochhaus A, Goldman J M, Cross N C
LRF Centre for Adult Leukaemia, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Br J Haematol. 1996 Mar;92(3):681-3. doi: 10.1046/j.1365-2141.1996.340858.x.
Recently the p16 and related p15 genes have been described as candidate tumour suppressors at chromosome 9p21. These genes have been found to be homozygously deleted at a high frequency in several types of solid tumours and also in acute lymphoid leukaemias. In order to determine whether these genes are more widely involved in haematological malignancies, we have investigated a total of 84 samples that did not have homozygous p16 or p15 deletions from patients with acute lymphoid leukaemia (n=13), acute myeloid leukaemia (n=24) and chronic myeloid leukaemia in blast crisis (n=43) as well as four haemopoietic cell lines. p15 and p16 exon 1 and exon 2 were amplified by polymerase chain reaction (PCR), analysed by single-stranded conformation polymorphism (SSCP) and subsequently by sequencing. Within the p16 gene, a G-->A polymorphism at nucleotide 436 was found in 3/80 (4%) leukaemias and the cell line HL60. This cell line had also a C-->T mutation at nucleotide 232 which causes a premature stop codon. Analysis of the p15 gene revealed a C-->A mutation within the noncoding sequence 27 nucleotides upstream of exon 2 in 10/80 (13%) cases. These data show that inactivation of either the p15 or p16 gene by point mutation is a very uncommon event in acute leukaemias.
最近,p16及相关的p15基因被描述为9号染色体p21区域的候选肿瘤抑制基因。这些基因在几种实体瘤以及急性淋巴细胞白血病中常出现高频纯合缺失。为了确定这些基因是否更广泛地参与血液系统恶性肿瘤,我们共研究了84个样本,这些样本来自急性淋巴细胞白血病患者(n = 13)、急性髓细胞白血病患者(n = 24)和急变期慢性髓细胞白血病患者(n = 43),均不存在p16或p15基因的纯合缺失,同时还研究了四种造血细胞系。通过聚合酶链反应(PCR)扩增p15和p16基因的外显子1和外显子2,采用单链构象多态性(SSCP)分析,随后进行测序。在p16基因中,在3/80(4%)的白血病样本及HL60细胞系中发现核苷酸436处存在G→A多态性。该细胞系在核苷酸232处还存在C→T突变,导致提前出现终止密码子。对p15基因的分析显示,在10/80(13%)的病例中,外显子2上游27个核苷酸的非编码序列内存在C→A突变。这些数据表明,在急性白血病中,点突变导致p15或p16基因失活是非常罕见的事件。